Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial.

Eshleman SH, Hudelson SE, Redd AD, Swanstrom R, Ou SS, Zhang XC, Ping LH, Piwowar-Manning E, Porcella SF, Sievers MF, Martens CA, Bruno D, Dukhovlinova E, McCauley M, Gamble T, Fogel JM, Sabin D, Quinn TC, Gunde L, Maliwichi M, Nhando N, Akelo V, Moyo S, Panchia R, Kumarasamy N, Chotirosniramit N, Melo MG, Pilotto J, Grinsztejn B, Mayer K, Chen YQ, Hughes JP, Cohen MS.

J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):112-116.

PMID:
27532476
2.

Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial.

Fogel JM, Hudelson SE, Ou SS, Hart S, Wallis C, Morgado MG, Saravanan S, Tripathy S, Hovind L, Piwowar-Manning E, Sabin D, McCauley M, Gamble T, Zhang XC, Eron JJ, Gallant JE, Kumwenda J, Makhema J, Kumarasamy N, Chariyalertsak S, Hakim J, Badal-Faesen S, Akelo V, Hosseinipour MC, Santos BR, Godbole SV, Pilotto JH, Grinsztejn B, Panchia R, Mayer KH, Chen YQ, Cohen MS, Eshleman SH.

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):304-9. doi: 10.1097/QAI.0000000000000951.

PMID:
26859828
3.

Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064.

Chen I, Clarke W, Ou SS, Marzinke MA, Breaud A, Emel LM, Wang J, Hughes JP, Richardson P, Haley DF, Lucas J, Rompalo A, Justman JE, Hodder SL, Eshleman SH.

PLoS One. 2015 Oct 7;10(10):e0140074. doi: 10.1371/journal.pone.0140074.

4.

Adherence to Early Antiretroviral Therapy: Results From HPTN 052, a Phase III, Multinational Randomized Trial of ART to Prevent HIV-1 Sexual Transmission in Serodiscordant Couples.

Safren SA, Mayer KH, Ou SS, McCauley M, Grinsztejn B, Hosseinipour MC, Kumarasamy N, Gamble T, Hoffman I, Celentano D, Chen YQ, Cohen MS; HPTN 052 Study Team..

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):234-40. doi: 10.1097/QAI.0000000000000593.

5.

HPTN 062: A Pilot Randomized Controlled Trial Exploring the Effect of a Motivational-Interviewing Intervention on Sexual Behavior among Individuals with Acute HIV Infection in Lilongwe, Malawi.

Pettifor A, Corneli A, Kamanga G, McKenna K, Rosenberg NE, Yu X, Ou SS, Massa C, Wiyo P, Lynn D, Tharaldson J, Golin C, Hoffman I; HPTN 062 Study Protocol Team..

PLoS One. 2015 May 11;10(5):e0124452. doi: 10.1371/journal.pone.0124452.

6.
7.

Walking speed in elderly outpatients depends on the assessment method.

Pasma JH, Stijntjes M, Ou SS, Blauw GJ, Meskers CG, Maier AB.

Age (Dordr). 2014;36(6):9736. doi: 10.1007/s11357-014-9736-y.

8.

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JH, Godbole SV, Chariyalertsak S, de Melo MG, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Havlir D, Cohen MS; HPTN 052-ACTG Study Team..

Lancet Infect Dis. 2014 Apr;14(4):281-90. doi: 10.1016/S1473-3099(13)70692-3. Erratum in: Lancet Infect Dis. 2014 Apr;14(4):269.

9.

HPTN 062: a feasibility and acceptability pilot intervention to reduce HIV transmission risk behaviors among individuals with acute and early HIV infection in Lilongwe, Malawi.

Corneli A, Pettifor A, Kamanga G, Golin C, McKenna K, Ou SS, Hamela G, Massa C, Martinson F, Tharaldson J, Hilgenberg D, Yu X, Chege W, Hoffman I; HPTN 062 study team..

AIDS Behav. 2014 Sep;18(9):1785-800. doi: 10.1007/s10461-014-0707-1.

10.

Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.

Kaleebu P, Njai HF, Wang L, Jones N, Ssewanyana I, Richardson P, Kintu K, Emel L, Musoke P, Fowler MG, Ou SS, Jackson JB, Guay L, Andrew P, Baglyos L, Cao H; HPTN 027 protocol team..

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):268-77. doi: 10.1097/01.qai.0000435600.65845.31.

11.

Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052).

Fogel JM, Wang L, Parsons TL, Ou SS, Piwowar-Manning E, Chen Y, Mudhune VO, Hosseinipour MC, Kumwenda J, Hakim JG, Chariyalertsak S, Panchia R, Sanne I, Kumarasamy N, Grinsztejn B, Makhema J, Pilotto J, Santos BR, Mayer KH, McCauley M, Gamble T, Bumpus NN, Hendrix CW, Cohen MS, Eshleman SH.

J Infect Dis. 2013 Nov 15;208(10):1624-8. doi: 10.1093/infdis/jit390.

12.
13.

Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa.

Kintu K, Andrew P, Musoke P, Richardson P, Asiimwe-Kateera B, Nakyanzi T, Wang L, Fowler MG, Emel L, Ou SS, Baglyos L, Gurunathan S, Zwerski S, Jackson JB, Guay L.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):1-8. doi: 10.1097/QAI.0b013e31827f1c2d.

14.

Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples.

Chen YQ, Masse B, Wang L, Ou SS, Li X, Donnell D, McCauley M, Gamble T, Ribauldo HJ, Cohen MS, Fleming TR.

Contemp Clin Trials. 2012 Nov;33(6):1280-6. doi: 10.1016/j.cct.2012.07.007.

15.

Comparison of a high-resolution melting assay to next-generation sequencing for analysis of HIV diversity.

Cousins MM, Ou SS, Wawer MJ, Munshaw S, Swan D, Magaret CA, Mullis CE, Serwadda D, Porcella SF, Gray RH, Quinn TC, Donnell D, Eshleman SH, Redd AD.

J Clin Microbiol. 2012 Sep;50(9):3054-9. doi: 10.1128/JCM.01460-12.

16.

Prevention of HIV-1 infection with early antiretroviral therapy.

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team..

N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243.

17.

Portal hypertension in children with Wilms' tumor: a report from the National Wilms' Tumor Study Group.

Warwick AB, Kalapurakal JA, Ou SS, Green DM, Norkool PA, Peterson SM, Breslow NE.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):210-6. doi: 10.1016/j.ijrobp.2009.04.057.

18.

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ.

J Clin Oncol. 2009 Jun 10;27(17):2766-71. doi: 10.1200/JCO.2008.18.9159.

19.

Satellite remote sensing of dust aerosol indirect effects on ice cloud formation.

Ou SS, Liou KN, Wang X, Hansell R, Lefevre R, Cocks S.

Appl Opt. 2009 Jan 20;48(3):633-42.

PMID:
19151835
20.
Items per page

Supplemental Content

Loading ...
Support Center